Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of hepatotoxicity and lipid metabolism-related toxicity on survival and quality of life in patients with high-volume metastatic hormone-sensitive prostate cancer treated with rezvilutamide in the CHART trial: a post hoc analysis.

BMC medicine·2026
Same author

Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2024
Same author

PLK1 as one novel target for the poor prognosis of bladder cancer: An observational study.

Medicine·2022
Same author

[KMT2A Activates Akt/mTOR Signaling Pathway Through LncRNA-HOTAIR to Influence the Biological Behavior of AML Cells].

Zhongguo shi yan xue ye xue za zhi·2022
Same author

The complete plastid genome sequence of <i>Neopicrorhiza scrophulariiflora</i> (Plantaginaceae): an endangered species endemic to The Himalayas regions.

Mitochondrial DNA. Part B, Resources·2020
Same author

Identification and Verification of Biomarker in Clear Cell Renal Cell Carcinoma via Bioinformatics and Neural Network Model.

BioMed research international·2020

Related Experiment Video

Updated: Dec 18, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.0K

Research progress on advanced renal cell carcinoma.

Xin-da Song1, Yi-Nong Tian2, Hao Li3

  • 1Department of Urinary Surgery, Graduate School of Peking Union Medical College, Beijing Hospital, National Center of Gerontology, Beijing, China.

The Journal of International Medical Research
|June 13, 2020
PubMed
Summary

Advanced renal cell carcinoma (RCC) is a serious urinary disease. This review covers current research on advanced RCC, focusing on personalized treatments for better patient outcomes.

Keywords:
Renal cell carcinomadiagnosisheterogeneitymetastaticpathophysiologytreatment

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.0K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.1K

Related Experiment Videos

Last Updated: Dec 18, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.0K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.0K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.1K

Area of Science:

  • Oncology
  • Urology
  • Cancer Research

Background:

  • Renal cell carcinoma (RCC) is the third most common urinary malignancy.
  • Over 350,000 individuals were affected by RCC in 2013, with nearly 140,000 annual deaths.
  • More than 30% of RCC patients experience relapse post-surgery due to metastatic spread.

Purpose of the Study:

  • To review current research on advanced renal cell carcinoma.
  • To discuss pathophysiology, heterogeneity, diagnosis, and treatment of advanced RCC.
  • To highlight personalized treatment strategies for advanced RCC patients.

Main Methods:

  • Literature review of extant research on advanced RCC.
  • Analysis of pathophysiology and tumor heterogeneity.
  • Evaluation of diagnostic and therapeutic approaches.

Main Results:

  • Advanced RCC presents significant challenges due to metastasis and relapse.
  • Tumor heterogeneity impacts treatment response.
  • Personalized treatment plans are crucial for managing advanced stages.

Conclusions:

  • Understanding RCC pathophysiology and heterogeneity is key for effective treatment.
  • Comprehensive, personalized therapies offer the most suitable approach for advanced RCC.
  • Further research is needed to improve survival and quality of life for advanced RCC patients.